Released Nov 1, 2018, after the close
10-Q filed Nov 1, 2018, 32 days after period end · 0001564590-18-026214
Q3 2018 · 10-Q
Revenue$1.03M$1.03M ±0.0% vs Q3 2017−0.1% vs Q2 2018
Net Income-$16.78M-$16.78M N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.31-$0.31 N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$16,692,000N/M
Operating Cash Flowderived-$3,556,000N/M
Free Cash Flowderived-$4,280,000N/M
Margins · derived
Operating margin-1626.9%−619.1 pt vs Q3 2017
Net margin-1635.7%−594.3 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | $1.03M | $1.03M |
| Net Income | -$16.78M | -$10.68M | -$8.74M | -$6.89M |
| EPS Diluted | -$0.31 | -$0.26 | -$0.27 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR